<div id="readability-page-1"><p>Abacus FCF Advisors LLC purchased a new stake in shares of  DaVita Inc. (NYSE:DVA - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 39,534 shares of the company's stock, valued at approximately $5,632,000. Abacus FCF Advisors LLC owned 0.05% of DaVita at the end of the most recent reporting period.</p><ul><li>Buffett's Latest Portfolio Moves, and Another Secret Stock</li></ul><p>A number of other institutional investors and hedge funds have also made changes to their positions in DVA. UMB Bank n.a. grew its stake in shares of  DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after buying an additional 76 shares during the last quarter.  Copia Wealth Management bought a new position in shares of  DaVita during the 4th quarter valued at $30,000.  National Pension Service grew its stake in shares of  DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company's stock valued at $30,000 after purchasing an additional 84 shares during the period.  Y.D. More Investments Ltd purchased a new stake in  DaVita during the first quarter valued at approximately $35,000.  Finally, NewEdge Advisors LLC raised its holdings in  DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company's stock worth $78,000 after purchasing an additional 88 shares during the period. Institutional investors own  90.12% of the company's stock. </p><h2>Insider Activity</h2><p>In other news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider owned 26,038 shares of the company's stock, valued at $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Corporate insiders own  1.50% of the company's stock. </p><h2>DaVita Trading Down 0.2%</h2><ul><li>Wall Street Is Cautious on These 2 First Half Winners</li></ul><p>Shares of NYSE DVA opened at $129.94 on Friday. DaVita Inc. has a 1-year low of $126.07 and a 1-year high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34. The business's 50 day moving average is $137.15 and its two-hundred day moving average is $141.02. The stock has a market capitalization of $9.29 billion, a P/E ratio of 12.78, a PEG ratio of 0.93 and a beta of 1.13. </p><p>DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm had revenue of $3.38 billion during the quarter, compared to analysts' expectations of $3.36 billion. During the same quarter in the previous year, the business earned $2.00 EPS. The company's quarterly revenue was up 6.1% on a year-over-year basis.  DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, research analysts expect that  DaVita Inc. will post 10.76 EPS for the current year. </p><h2>Analysts Set New Price Targets</h2><ul><li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li></ul><p>A number of analysts have recently issued reports on DVA shares. Barclays reduced their price objective on shares of DaVita from $169.00 to $160.00 and set an &#34;equal weight&#34; rating for the company in a research note on Thursday, August 7th. Wall Street Zen upgraded DaVita from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, September 13th. Bank of America lowered their price objective on DaVita from $145.00 to $140.00 and set an &#34;underperform&#34; rating on the stock in a research report on Wednesday, September 10th. Finally, Truist Financial  set a $148.00 price objective on DaVita in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Hold rating and one  has assigned  a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Reduce&#34; and an average price target of $158.00.</p><p><b>View Our Latest Analysis on DaVita</b></p><h2>DaVita Company Profile</h2> (Free Report)<p>DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.</p><h2>Read More</h2><ul><li>Five stocks we like better than DaVita</li><li>What is a Bond Market Holiday? How to Invest and Trade</li><li>Caterpillar Stock Hits All-Time High—Is There More Room to Run?</li><li>What is a buyback in stocks? A comprehensive guide for investors</li><li>Berkshire-Backed Lennar Slides After Weak Q3 Earnings</li><li>What is a Dividend King? </li><li>Analysts Turn Bullish on Hershey—Is Pepsi the Next Value Play?</li></ul><p><strong>Want to see what other hedge funds are holding DVA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURWQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURWQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in DaVita Right Now?</h2><p>Before you consider DaVita, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.</p><p>While DaVita currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Abacus FCF Advisors LLC acquired 39,534 shares of DaVita Inc. (NYSE:DVA) valued at approximately $5.6 million in Q2, according to a recent SEC filing. Other institutional investors also increased their stakes in DaVita. The company reported a Q2 EPS of $2.95, exceeding estimates, with a revenue of $3.38 billion. Analysts have mixed ratings on DaVita, with price targets ranging from $140 to $160. DaVita operates kidney dialysis services in the U.S.</p>

39,534 Shares in DaVita Inc. $DVA Purchased by Abacus FCF Advisors LLC